<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8432">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834236</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS96-CT2-24</org_study_id>
    <nct_id>NCT00834236</nct_id>
  </id_info>
  <brief_title>Proteiomic Fingerprints of Gastric Juice</brief_title>
  <official_title>Diagnosis of Gastroduodenal Diseases by Proteiomic Fingerprints of Gastric Juice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No accurate, inexpensive and non-invasive test for gastric cancer screening is currently
      available. The investigators' recent study identified a1-antitrypsin and other proteins as
      potential biomarkers of gastric cancer in gastric juice. The aim of this study was to
      develop a novel non-invasive modality for detecting gastric cancer by measurement of
      biomarkers in gastric juice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and methods: The study consisted of two parts: (1) investigating the differences in
      gastric juice biomarker concentrations between gastric cancer patients and controls, and (2)
      screening gastric cancer using string test to obtain gastric juice followed by immunoassay
      for biomarker concentration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Number of Participants With Accurate Diagnosis for Gastric Cancer</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normal subject group: number of the subjects with normal alpha 1-antitrypsin level in gastric juice Gastric cancer group: number of the subjects with elevated alpha 1-antitrypsin level in gastric juice</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gastric cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal subject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal subject</intervention_name>
    <description>biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA</description>
    <arm_group_label>gastric cancer</arm_group_label>
    <arm_group_label>normal subject</arm_group_label>
    <other_name>biomarker in gastric juice</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gastric cancer</intervention_name>
    <description>biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
    <arm_group_label>gastric cancer</arm_group_label>
    <arm_group_label>normal subject</arm_group_label>
    <other_name>biomarker in gastric juice</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subjects and gastric cancer patients documented by endoscopy.

        Exclusion Criteria:

          -  the use of proton pump inhibitors or histamine-2 receptor antagonists within 4 weeks
             prior to the study

          -  coexistence of two kinds of gastroduodenal lesions

          -  coexistence of severe systemic diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping-I Hsu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans Genaral hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>November 3, 2015</lastchanged_date>
  <firstreceived_date>February 2, 2009</firstreceived_date>
  <firstreceived_results_date>September 30, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Ping-I (William) Hsu, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>proteomics</keyword>
  <keyword>gastric juice</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gastric Cancer</title>
          <description>gastric cancer patients
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
        </group>
        <group group_id="P2">
          <title>Normal Subject</title>
          <description>healthy subject
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gastric Cancer</title>
          <description>gastric cancer patients
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
        </group>
        <group group_id="B2">
          <title>Normal Subject</title>
          <description>healthy subject
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.5" spread="14.3"/>
                <measurement group_id="B2" value="51.4" spread="14.9"/>
                <measurement group_id="B3" value="59.5" spread="14.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Taiwan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Accurate Diagnosis for Gastric Cancer</title>
        <description>Normal subject group: number of the subjects with normal alpha 1-antitrypsin level in gastric juice Gastric cancer group: number of the subjects with elevated alpha 1-antitrypsin level in gastric juice</description>
        <time_frame>2 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Gastric Cancer</title>
            <description>gastric cancer patients
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
          </group>
          <group group_id="O2">
            <title>Normal Subject</title>
            <description>healthy subject
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Accurate Diagnosis for Gastric Cancer</title>
            <description>Normal subject group: number of the subjects with normal alpha 1-antitrypsin level in gastric juice Gastric cancer group: number of the subjects with elevated alpha 1-antitrypsin level in gastric juice</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gastric Cancer</title>
          <description>gastric cancer patients
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
        </group>
        <group group_id="E2">
          <title>Normal Subject</title>
          <description>healthy subject
normal subject: biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancer: biomarker in gastric juice, e.g., alpha 1-antitrypsin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was performed in a single country</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ping-I Hsu</name_or_title>
      <organization>Kaohsiung Veterans General Hospital</organization>
      <phone>+886-7-3422121 ext 8233</phone>
      <email>pihsu@vghks.gov.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
